王朝华;曾浩霞;昌晓红;付天云;成夜霞;倪俊;崔恒;

• 1:北京大学人民医院妇科肿瘤中心

摘要(Abstract)：

目的:研究紫杉醇化疗中应用地塞米松对血糖代谢的影响并分析其机制。方法:随机将80只Wistar大鼠分为8组,实验组预处理地塞米松后予以紫杉醇和卡铂,以生理盐水、地塞米松、紫杉醇、卡铂、地塞米松+紫杉醇、地塞米松+卡铂和紫杉醇+卡铂等7组为对照组。分别在给药前与给药后4,7,14天取大鼠空腹和糖负荷后1h、2h血清,测定血糖、胰岛素和胰高血糖素并比较。结果:紫杉醇、卡铂给药后可观察到一过性血糖升高。其中紫卡组给药后4天1h血糖(P=0.025)、给药后7天空腹(P=0.003)和1h血糖(P=0.045)显著升高,给药后14天恢复(P=0.165)。紫杉组给药后4天1h血糖(P=0.008)和给药后14天空腹血糖(P=0.003)升高。地米组与阴性对照组比较1h血糖略升(P>0.05),但与化疗药物合用时,血糖降低。紫卡组给药后胰高血糖素升高,糖负荷后胰岛分泌指数下降,加用地塞米松有改善的趋势。结论:紫杉醇卡铂化疗中加入地塞米松可以降低血糖升高程度和减弱胰高血糖素、胰岛素的负面变化,有利于血糖稳定。它在含紫杉醇化疗方案中调节血糖的作用及机制,有待进一步的多疗程实验研究。

关键词(KeyWords)： 地塞米松;紫杉醇;卡铂;血糖;胰岛素;胰高血糖素;大鼠,Wistar;药物疗法

Abstract:

Keywords:

基金项目(Foundation):

作者(Authors): 王朝华;曾浩霞;昌晓红;付天云;成夜霞;倪俊;崔恒;

DOI: 10.13283/j.cnki.xdfckjz.2010.03.028

参考文献(References)：

• [1]McGuire WP,Hoskins WJ,Brady MF,et al.Cyclophospha-mide and cisplatin compared with paclitaxel and cisplatin in patients with stageⅢand stage IV ovarian cancer[J].N Engl J Med,1996,334:1-6
• [2]Chang AY,Rubins J,Asbury R,et al.Weekly paclitaxel in advancel non-small cell lung cancer[J].Semin Oncol,2001,28:10-13
• [3]Fidias P,Supko JG,Martins R,et al.A phaseⅡstudy of weekly paclitaxel in elderly patients with advanced non-small cell lung cancer[J].Clin Cancer Res,2001,7:3942-3949
• [4]王朝华,崔恒,李小平,等.妇科恶性肿瘤化疗后发生糖尿病患者的临床分析[J].中国妇产科临床,2002,3:13-15
• [5]王朝华,崔恒,李小平,等.化疗后糖尿病发病相关因素的分析[J].中国妇产科临床杂志2004,5:416-419
• [6]Gearhart MM,Parbhoo SK.Hyperglycemia in the critically ill patient[J].AACN Clin Issues,2006,17:50-55
• [7]Dansuntornwong B,Chanprasertyothin S,Jongjaroenprasert W,et al.The relation between parameters from homeosta-sis model assessment and glycemic control in type2diabe-tes[J].J Med Assoc Thai,2007,90:2284-2290
• [8]Yan X,Wong P,DelPriore G,et al.Chemotherapy-associ-ated steroid use and its effect on blood glucose,nephro-,and other toxicity of chemotherapy for non-diabetic onco-logical patients[J].J Clin Oncol,2009ASCO Annual Meeting Proceedings(Post-Meeting Edition).2009,27:e20721
• [9]Rosenberg AJE,Halabia S,Sanford BL,et al.Small1phaseⅡstudy of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma:CAL-GB90207[J].Annals of Oncology,2008,19:946-950
• [10]Ozols RF.Update of the NCCN ovarian cancer practice guidelines[J].Oncology(Williston park),1997,11:95-105